CanniMed Therapeutics Inc (TSE:CMED) insider Larry Holbrook sold 5,000 shares of the company’s stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of C$10.25, for a total value of C$51,250.00.

Larry Holbrook also recently made the following trade(s):

  • On Monday, September 18th, Larry Holbrook sold 1,000 shares of CanniMed Therapeutics stock. The shares were sold at an average price of C$9.41, for a total value of C$9,410.00.
  • On Monday, July 31st, Larry Holbrook sold 100 shares of CanniMed Therapeutics stock. The shares were sold at an average price of C$10.05, for a total value of C$1,005.00.

CanniMed Therapeutics Inc (TSE CMED) traded up 3.04% during mid-day trading on Thursday, hitting $11.85. The stock had a trading volume of 121,734 shares. The company has a 50-day moving average of $9.70 and a 200-day moving average of $9.70. The firm’s market cap is $272.05 million. CanniMed Therapeutics Inc has a 12-month low of $8.80 and a 12-month high of $13.10.

COPYRIGHT VIOLATION NOTICE: “CanniMed Therapeutics Inc (CMED) Insider Larry Holbrook Sells 5,000 Shares” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at

CanniMed Therapeutics Company Profile

CanniMed Therapeutics Inc is a Canada-based plant biopharmaceutical company. It is specialized in the production of pharmaceutical-grade cannabis and offers a range of pharmaceutical-grade cannabis products. In addition, the Company has a plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.

Insider Buying and Selling by Quarter for CanniMed Therapeutics (TSE:CMED)

Receive News & Ratings for CanniMed Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CanniMed Therapeutics Inc and related companies with's FREE daily email newsletter.